Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Autosomal recessive form of limb-girdle muscular dystrophy.
No HPO annotations are available for this condition.
Age of onset: later in life, adolescence, childhood, newborn period, middle age, adulthood.
Dysferlinopathy includes a spectrum of muscle disease characterized by two major phenotypes (Miyoshi muscular dystrophy [MMD] and limb-girdle muscular dystrophy type 2B [LGMD2B]) and two minor phenotypes (asymptomatic hyperCKemia and distal myopathy with anterior tibial onset [DMAT]) . The major and minor phenotypes can occur within families having the same pathogenic variants [, , , , ]. The weakness and atrophy may be asymmetric with any of these presentations. Miyoshi muscular dystrophy. Young adults have muscle weakness and atrophy most marked in the distal part of the legs, especially the gastrocnemius and soleus muscles. Early on, affected individuals are not able to stand on tiptoe, but retain the ability to stand on the heels. Over a period of years, the weakness and atrophy spread to the thighs and gluteal muscles, at which time climbing stairs, standing, and walking become difficult. The forearms may become mildly atrophic with decrease in grip strength; the small muscles of the hands are spared. The weakness may eventually include the shoulder girdle muscles . Limb-girdle muscular dystrophy type 2B is characterized by early weakness and atrophy of the pelvic and shoulder girdle muscles that begins in adolescence or young adulthood, with slow progression. The spectrum of muscle involvement can also on occasion manifest as the scapuloperoneal syndrome with initial weakness of the shoulder girdle muscles combined with distal weakness of the legs or congenital muscular dystrophy with early onset – as observed, for example, in two sibs with hypotonia beginning between birth and age two months who had delayed motor development and serum CK concentrations that were normal or slightly elevated before age three years . Asymptomatic hyperCKemia. Some individuals have only a marked elevation of serum CK concentration. This is usually considered a presymptomatic presentation of myopathy in an individual who eventually develops muscle weakness and atrophy. Sometimes the calf muscles are enlarged; this presentation may be confused with a dystrophinopathy (i.e., Duchenne or Becker muscular dystrophy). Distal myopathy with anterior tibial onset is characterized by leg weakness that involves the muscles of the anterior compartment of the leg, causing foot drop . Table 2. Dysferlinopathy: Comparison of Phenotypes by Select Features
No consensus clinical diagnostic criteria for dysferlinopathy have been published.
Dysferlinopathy should be suspected in those with suggestive findings of and considered in those with suggestive findings of . The diagnosis should be informed by .
Dysferlinopathy should be suspected in individuals with suggestive findings of the two major phenotypes, Miyoshi muscular dystrophy and limb-girdle muscular dystrophy 2B, based on the following findings . Miyoshi muscular dystrophy (MMD)
No approved treatments are currently available for autosomal recessive limb-girdle muscular dystrophy. The disease remains an area of unmet medical need.
No clinical practice guidelines for dysferlinopathy have been published.
To establish the extent of disease and needs in an individual diagnosed with dysferlinopathy, the evaluations summarized (if not performed as part of the evaluation that led to the diagnosis) are recommended.
Routine follow up with the multidisciplinary team (annually or more frequently as determined by managing physician) is recommended. See .
Table 6.
Dysferlinopathy: Recommended Multidisciplinary Team Surveillance
System/Concern | Evaluation | Frequency
| Evaluate disease progression coordinate care. | At least annually
No clinical trials have been registered for autosomal recessive limb-girdle muscular dystrophy.
59 publications have been identified in PubMed for autosomal recessive limb-girdle muscular dystrophy. Research spans Case Report / Case Series (39%), Basic Science / Preclinical (20%), and Epidemiology / Natural History (15%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 23 | 39% |
Data assembled from 4 of 12 sources · Last updated Sep 19, 2026, 11:45 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Feature | MMD | LGMD2B |
|---|---|---|
Percent | 49.8%1 | 39.2%1 |
Mean age at onset (range) | 22.1 yrs1(10-48) | 28.2 yrs1(10-63) |
Average age when use of a cane is required (yrs after onset) | 35.5 yrs2(16 yrs) | 39.3 yrs2(13.6 yrs) |
Age when wheelchair bound (yrs after onset) | 42.8 yrs2(22.8 yrs) | 45.1 yrs2(21.4 yrs) |
Median CK level | 4,4401 | 3,4811 |
Cardiac complications | 3.6%3 | Asymptomatic |
Respiratory complications | 22.8%3 | Asymptomatic |
Source: GeneReviews — "Dysferlinopathy"
Source: GeneReviews — "Dysferlinopathy"
Limb-girdle muscular dystrophies. Dysferlinopathy needs to be distinguished from other autosomal recessive limb-girdle muscular dystrophies (see OMIM Phenotypic Series: LGMD, autosomal recessive). Individuals with LGMD generally show weakness and wasting restricted to the limb musculature, proximal greater than distal. Most individuals with LGMD show relative sparing of the heart and bulbar muscles, although exceptions occur depending on the genetic subtype. Onset, progression, and distribution of the weakness and wasting vary considerably among individuals and genetic subtypes. Multigene panels are increasingly used to identify pathogenic variants and confirm a diagnosis of a specific form of LGMD. Dystrophinopathies.
Source: GeneReviews — "Dysferlinopathy"
Biomarker and diagnostic research for autosomal recessive limb-girdle muscular dystrophy has been reported in the published literature.
Dysferlinopathy: Recommended Evaluations Following Initial Diagnosis
System/Concern | Evaluation | Comment
| Neuromuscular, physical medicine rehab / PT/OT eval | To evaluate extent of disease as determined by:
Muscle strength function in arms, hands, legs (esp calves), feet
Balance
Function
Fine motor skills
Impact on activities of daily living
Need for ongoing PT OT
Need for AFOs assistive ambulatory devices
Need for adaptive devices
Need for handicapped parking
| PFTs incl supine sitting spirometry, MIP, MEP | To evaluate for effects of muscle weakness on respiratory function, esp in nonambulatory persons
| Baseline echocardiogram | To evaluate for evidence of cardiac involvement (cardiomegaly, cardiomyopathy, arrhythmia)
Genetic
counseling | By a genetics professional1 | To review results of genetic testing to inform patients families re nature, MOI implications of dysferlinopathy in order to facilitate medical personal decision making
Family support/
resources | Assess:
Use of community or , incl patient advocacy organizations;
Need for social work involvement for caregiver support.
Source: GeneReviews — "Dysferlinopathy"
Control weight to avoid obesity; avoid use of steroids .
Source: GeneReviews — "Dysferlinopathy"
Comparison of the effect of prednisolone with vamorolone on dysferlin-deficient myofiber repair showed that vamorolone stabilized dysferlin-deficient muscle cell membrane and improved repair of dysferlin-deficient mouse myofibers . Exon skipping is a therapeutic approach that is feasible for various genetic disorders . designed antisense oligonucleotides (AONs) to bypass the effect of the affected individuals pathogenic variant on RNA splicing. AON-mediated exon skipping corrected the aberrant pseudoexon splicing events in vitro, which increased normal mRNA production and significantly restored dysferlin protein expression .
Source: GeneReviews — "Dysferlinopathy"
View trials for autosomal recessive limb-girdle muscular dystrophy
Rehabilitation
medicine | Eval monitoring of:
Muscle strength testing using a quantitative scale (e.g., MMT, hand-held dynamometry, QMA1) to evaluate progressive muscle involvement
Physical function (e.g., 6-min walk test, AMAT2)
Activities of daily living
| At least annually
PT | Eval mgmt for balance need for AFOs, cane, walker, wheelchair. powerchair | At least annually, or more frequently based on needs
OT | Eval mgmt of fine motor skills hand function, such as Jebsen Hand Function Test3 | At least annually
| PFTs incl supine sitting spirometry, MIP, MEP on affected persons at advanced stages of disease | As needed, if symptomatic or abnormal PFTs
| Follow up not needed unless symptomatic or findings on initial eval were abnormal
Family support/
resources | Assess social emotional support stimulation. | At least annually
AFOs = ankle-foot orthoses; AMAT = Adult Myopathy Assessment Tool; MEP = maximal expiratory pressure; MIP = maximal inspiratory pressure; MMT = manual muscle testing; OT = occupational therapy; PFTs = pulmonary function tests; PT = physical therapy; QMA = Quantitative Muscle Assessment
1.
2.
3.
Source: GeneReviews — "Dysferlinopathy"
Laboratory research |
12 |
20% |
Disease patterns and progression | 9 | 15% |
New treatment approaches | 6 | 10% |
Research summaries | 4 | 7% |
Testing and diagnosis research | 3 | 5% |
Clinical study results | 2 | 3% |
Abdel Aleem AF (2026). [PMID: 41633215](https://pubmed.ncbi.nlm.nih.gov/41633215/). *Pediatric neurology*. [Case Report / Case Series]
Sakhaei A (2026). [PMID: 41721539](https://pubmed.ncbi.nlm.nih.gov/41721539/). *Cell journal*. [Case Report / Case Series]
Guérémy A (2026). [PMID: 41943552](https://pubmed.ncbi.nlm.nih.gov/41943552/). *Muscle Nerve*. [Epidemiology / Natural History]
Mouloudi N (2026). [PMID: 41954144](https://pubmed.ncbi.nlm.nih.gov/41954144/). *Acta Myol*. [Epidemiology / Natural History]
Bruge C (2026). [PMID: 41869723](https://pubmed.ncbi.nlm.nih.gov/41869723/). *JCI Insight*. [Basic Science / Preclinical]
Baine S (2026). [PMID: 41194675](https://pubmed.ncbi.nlm.nih.gov/41194675/). *Human gene therapy*. [Gene Therapy / Novel Therapeutics]
Villa C (2026). [PMID: 42225003](https://pubmed.ncbi.nlm.nih.gov/42225003/). *Stem Cell Res*. [Basic Science / Preclinical]
El-Hayek S (2026). [PMID: 41904993](https://pubmed.ncbi.nlm.nih.gov/41904993/). *J Neuromuscul Dis*. [Case Report / Case Series]
Datta AK (2026). [PMID: 40952715](https://pubmed.ncbi.nlm.nih.gov/40952715/). *JAMA neurology*. [Case Report / Case Series]
Nakamura N (2026). [PMID: 41824290](https://pubmed.ncbi.nlm.nih.gov/41824290/). *FASEB journal : official publication of the Federation of American Societies for Experimental Biology*. [Case Report / Case Series]